Stockscreener 앱 받기
21.94
3.01%
-0.68
전일 마감가:
$22.62
열려 있는:
$21.97
하루 거래량:
648.32K
Relative Volume:
0.92
시가총액:
$860.97M
수익:
순이익/손실:
$-74.31M
주가수익비율:
-8.8407
EPS:
-2.4817
순현금흐름:
$-62.86M
1주 성능:
-9.97%
1개월 성능:
-26.87%
6개월 성능:
-15.81%
1년 성능:
+273.13%
1일 변동 폭
$21.71
$22.63
1주일 범위
$21.32
$25.25
52주 변동 폭
$5.71
$37.48
Alto Neuroscience Inc Stock (ANRO) Company Profile
명칭
Alto Neuroscience Inc
전화
773-255-5012
주소
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
21.94 | 860.97M | 0 | -74.31M | -62.86M | -2.4817 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-05-22 | 개시 | Wolfe Research | Outperform |
| 2026-05-05 | 개시 | BofA Securities | Buy |
| 2026-01-05 | 재개 | Chardan Capital Markets | Buy |
| 2025-11-17 | 개시 | BTIG Research | Buy |
| 2025-09-29 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-23 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-09-03 | 개시 | Wedbush | Outperform |
| 2024-02-27 | 개시 | Jefferies | Buy |
| 2024-02-27 | 개시 | Robert W. Baird | Outperform |
| 2024-02-27 | 개시 | Stifel | Buy |
| 2024-02-27 | 개시 | TD Cowen | Outperform |
| 2024-02-27 | 개시 | William Blair | Outperform |
모두보기
Alto Neuroscience Inc 주식(ANRO)의 최신 뉴스
Here's Why You Should Add ANRO Stock to Your Portfolio Now - Zacks Investment Research
At $2.32 a share, Alto Neuroscience (ANRO) CFO exercises options for 55,000 shares. - Stock Titan
Alto Neuroscience Insider Sold Shares Worth $3,567,247, According to a Recent SEC Filing - Moomoo
Alto Neuroscience(ANRO.US) Officer Sells US$3.57 Million in Common Stock - Moomoo
Form 4 Alto Neuroscience Inc For: 1 October By Investing.com - Investing.com South Africa
Form 4 Alto Neuroscience Inc For: 1 October By Investing.com - Investing.com Nigeria
Alto Neuroscience president and CFO Smith sells $3.57m in shares - Investing.com
Alto Neuroscience president and CFO Smith sells $3.57m in shares - Investing.com India
Exercising options at $2.35, Alto Neuroscience (ANRO)'s CFO sells shares. - Stock Titan
Alto Neuroscience President And CFO Sold Shares Worth Over $3.5M - TradingView
Stock options underpin an officer's proposed share sale at Alto Neuroscience (NYSE: ANRO). - Stock Titan
Alto Neuroscience, Inc.(NYSE: ANRO) added to S&P Global BMI Index - marketscreener.com
Alto Neuroscience Announces Participation in Upcoming September 2026 Investor Conferences - BioSpace
Alto Neuroscience announces September participation in investor conferences - Traders Union
Alto Neuroscience Announces Participation in Upcoming Investor Conferences - Business Wire
Alto Neuroscience Announces Participation in Upcoming Investor Conferences - Yahoo Finance
ANRO News | ALTO NEUROSCIENCE INC (NYSE:ANRO) - ChartMill
Alto Neuroscience Promotes Nick Smith to President and CFO - Contract Pharma
Alto Neuroscience Elevates Nicholas C. Smith to President and CFO with $6 Million Retention Deal - Kalkine Media
Nicholas C. Smith promoted to President and CFO at Alto Neuroscience - TradingView
Alto Neuroscience promotes Nick Smith to president and CFO By Investing.com - Investing.com India
Alto Neuroscience promotes Nick Smith to president and CFO By Investing.com - Investing.com Canada
Alto Neuroscience promotes Nick Smith to president and CFO By Investing.com - Investing.com UK
Alto Neuroscience, Inc. Promotes Nick Smith to President, Effective August 26, 2026 - marketscreener.com
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer - Yahoo Finance
Alto Neuroscience stock hits all-time high at 35.42 USD By Investing.com - Investing.com India
Alto Neuroscience stock hits all-time high at 35.42 USD - Investing.com
Alto Neuroscience stock hits all-time high at 35.42 USD By Investing.com - Investing.com UK
HC Wainwright Issues Optimistic Forecast for ANRO Earnings - MarketBeat
H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $55 - Moomoo
H.C. Wainwright raises Alto Neuroscience price target to $55 - Investing.com India
H.C. Wainwright raises Alto Neuroscience price target to $55 - Investing.com
H.C. Wainwright raises Alto Neuroscience price target to $55 By Investing.com - Investing.com Canada
H.C. Wainwright raises Alto Neuroscience price target to $55 - Investing.com
Alto Neuroscience (NYSE:ANRO) Reaches New 1-Year High on Analyst Upgrade - MarketBeat
HC Wainwright Increases Alto Neuroscience (NYSE:ANRO) Price Target to $55.00 - MarketBeat
Is Alto Neuroscience (ANRO) Fully Valued As ALTO 207 Expands With New Funding? - Sahm
Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued? - Yahoo Finance
Are Alto Neuroscience’s (ANRO) Rising Losses Funding a Stronger Depression Pipeline or Diluting Discipline? - Yahoo Finance
Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans - Yahoo Finance
Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding - Sahm
Alto Neuroscience (ANRO) Slips 0.5% as Stock Holds Above Key $30.53 SupportFund Manager Survey - vinanet.vn
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC) - The Globe and Mail
Alto Neuroscience (ANRO) Slips 0.5% as Stock Holds Above Key $30.53 SupportCalendar Spread Trade - dars.gov.et
Alto Neuroscience (NYSE:ANRO) Upgraded to "Sell" at Wall Street Zen - MarketBeat
Alto Neuroscience (ANRO) investor group discloses 9.99% ownership cap - Stock Titan
Vestal Point Capital (ANRO) discloses 785,000-share Alto Neuroscience position in 13G/A - Stock Titan
BofA Securities Maintains Alto Neuroscience(ANRO.US) With Buy Rating - Moomoo
Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding - simplywall.st
Alto Neuroscience (NYSE:ANRO) Stock Price Down 4.7%Here's Why - MarketBeat
Alto Neuroscience Inc (ANRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alto Neuroscience Inc 주식 (ANRO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Smith Nicholas Conrad | PRESIDENT AND CFO |
Sep 30 '26 |
Option Exercise |
2.35 |
24,056 |
56,532 |
48,116 |
| Smith Nicholas Conrad | PRESIDENT AND CFO |
Sep 30 '26 |
Sale |
25.82 |
24,056 |
621,097 |
24,060 |
| Smith Nicholas Conrad | PRESIDENT AND CFO |
Sep 29 '26 |
Sale |
26.58 |
110,830 |
2,946,150 |
24,060 |
| NICHOLAS SMITH | Officer |
Sep 29 '26 |
Proposed Sale |
26.66 |
134,886 |
3,596,061 |
0 |
| Smith Nicholas Conrad | PRESIDENT AND CFO |
Sep 29 '26 |
Option Exercise |
2.35 |
110,830 |
260,450 |
134,890 |
2.71%
자본화:
|
볼륨(24시간):